FK PC101
Alternative Names: FK-PC101Latest Information Update: 01 Feb 2024
At a glance
- Originator FK-Biotecnologia SA
- Class Cancer vaccines; Cell therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Prostate cancer
- No development reported Breast cancer; Gastric cancer; Malignant melanoma
Most Recent Events
- 29 Jan 2024 CellVax Therapeutics receives clearance for its IND application for FK PC101 for Prostate cancer
- 20 Dec 2023 CellVax plans a phase II trial for Prostate cancer in the US by March 2024
- 20 Dec 2023 CellVax and Theragent files an IND application with the US FDA for phase II trial Prostate cancer